Stockreport

ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF IBRX faces formidable competition from JNJ's Inlexzo, which demonstrates superior efficacy and commercial advantages, threatening Anktiva's long-term market share. De [Read more]